Cancer Vaccines at ESMO 2026

For decades, cancer vaccines have presented a persistent challenge in oncology, despite strong biological rationale and technological advances, translating immune activation into meaningful and durable clinical outcomes has remained difficult. Earlier tumor-associated antigen vaccines often stimulated immune responses without producing sustained patient benefit. The challenge extended beyond vaccine design to selecting relevant tumor targets, generating durable immunity, overcoming the immunosuppressive tumor microenvironment and demonstrating a meaningful impact on disease progression.

As the field approaches ESMO 2026, the landscape has evolved considerably. Advances in tumor sequencing, computational biology, neoantigen prediction, immunopeptidomics, mRNA and peptide platforms, and immune checkpoint inhibition are enabling a more precise approach to therapeutic vaccination. Instead of targeting broadly expressed tumor antigens, newer strategies increasingly focus on identifying mutations specific to an individual tumor and using them to direct a targeted immune response. This evolution is shifting the central question from “Can a cancer vaccine generate an immune response?” to “Can a precisely selected tumor antigen generate a durable immune response that changes clinical outcomes?” ESMO 2026 is therefore important not because cancer vaccines are suddenly a new concept, but because the field is approaching a point at which clinical validation, antigen biology, manufacturing and long-term immune memory can be assessed together. 

From Neoantigen Prediction to Biologically Validated Antigens

One of the most important developments in the field is the growing recognition that predicting a neoantigen from tumor sequencing is not sufficient. A mutation may be theoretically immunogenic but never become a biologically relevant target if the resulting peptide is not processed, presented by human leukocyte antigen (HLA) molecules, or recognized by T cells.

This has elevated the tumor immunopeptidome the collection of peptides actually presented by tumor cells through HLA molecules from a research concept to an increasingly important component of vaccine development. Direct identification of tumor-derived HLA-bound peptides can help distinguish theoretically predicted targets from antigens that are genuinely visible to the immune system. ESMO has highlighted three potential models emerging from this approach: conventional off-the-shelf vaccines targeting common antigens or HLA contexts; pre-manufactured libraries of immunopeptidome-defined antigens that can subsequently be assembled into patient-specific products; and fully individualized vaccines generated from each patient's tumor profile.

This distinction could become one of the most important competitive differentiators in the next generation of cancer vaccines. The value of personalization may ultimately depend less on the ability to manufacture a unique product and more on whether the selected targets accurately represent the biology of the patient's tumor.

Intismeran Autogene Moves the Field Toward Clinical Validation

The most important cancer-vaccine development heading into ESMO 2026 is likely to be intismeran autogene (V940; formerly mRNA-4157). The program has moved beyond the proof-of-concept stage and into the territory where the central question is whether an individualized neoantigen vaccine can produce clinically meaningful benefit on top of established immunotherapy.

In August 2026, Merck and Moderna announced positive topline results from the Phase III INTerpath-001 study in 1,137 patients with completely resected stage IIB, IIC, III or IV cutaneous melanoma. Patients were randomized to receive intismeran autogene plus pembrolizumab or pembrolizumab alone. The trial met its primary endpoint of recurrence-free survival and its key secondary endpoint of distant metastasis-free survival. Overall survival follow-up remains ongoing.

The significance of this result extends beyond another positive melanoma trial. INTerpath-001 represents a test of whether an individualized neoantigen approach can generate incremental benefit over an established checkpoint inhibitor in the adjuvant setting. Importantly, ESMO 2026 is not the point at which the vaccine's efficacy will first become known; the positive topline result has already been announced. Instead, the detailed presentation is important for understanding the magnitude, durability, consistency across patient subgroups, safety profile and relationship between immune response and clinical outcome.

The development trajectory is supported by earlier Phase IIb evidence. In the five-year update of KEYNOTE-942, the combination demonstrated a 49% reduction in the risk of recurrence or death compared with pembrolizumab alone (HR 0.51) and a 59% reduction in the risk of distant metastasis or death (HR 0.411). An exploratory overall survival analysis also favored the combination, although the study was not powered to establish definitive OS benefit.

These findings establish an important progression in the evidence base: the vaccine is no longer being evaluated solely on whether it can induce neoantigen-specific T cells. The development program is now asking whether those immune responses translate into longer periods without recurrence or metastatic disease.

Why the Adjuvant Setting Matters

The melanoma program also illustrates an important strategic consideration: the biological setting in which a cancer vaccine is administered may be as important as the vaccine itself.

After complete surgical resection, tumor burden is substantially lower than in advanced metastatic disease. The immune system may therefore face a smaller and more manageable population of residual malignant cells. A vaccine can potentially expand and maintain tumor-specific T-cell populations before extensive immune dysfunction and tumor heterogeneity have developed.

This does not mean that the adjuvant setting is universally superior. Rather, it suggests that cancer vaccines may have a particularly strong rationale when used to eliminate microscopic residual disease rather than attempting to reverse established, immunologically complex metastatic disease.

The emerging development model therefore increasingly combines three components:

• Tumor-specific antigen selection
• Immune activation through vaccination
• Checkpoint inhibition to sustain T-cell function

The resulting therapeutic concept is less a standalone vaccine and more an integrated immunotherapy regimen.

Pancreatic Cancer Provides a Different Proof Point: Immune Memory

While melanoma provides the most advanced clinical validation, pancreatic cancer offers some of the most compelling biological evidence for the durability of individualized vaccination.

In a Phase I study of autogene cevumeran in resected pancreatic ductal adenocarcinoma, 8 of 16 evaluable patients developed vaccine-induced neoantigen-specific T-cell responses. At a median follow-up of approximately 3.2 years, patients who generated vaccine-induced responses had not reached median recurrence-free survival, compared with 13.4 months among non-responders; the reported hazard ratio was 0.14.

Perhaps more important for the long-term development of cancer vaccines, vaccine-induced CD8 T-cell clones demonstrated substantial persistence. Investigators estimated an average clone lifespan of approximately 7.7 years, with many vaccine-induced clones remaining detectable several years after vaccination. These observations are scientifically important because pancreatic cancer has traditionally been considered one of the most challenging tumor types for immunotherapy. The findings suggest that a properly selected neoantigen vaccine can establish immune memory capable of persisting well beyond the initial treatment period.

However, these data should not be interpreted as definitive evidence of efficacy. The study was small and non-randomized, and only a subset of patients developed measurable vaccine-induced responses. Its primary importance lies in demonstrating that individualized vaccination can generate durable, tumor-specific immune memory in a disease where conventional immunotherapy has historically struggled. The study also highlights a fundamental challenge: tumors evolve. In patients who eventually experienced recurrence, tumor analysis suggested loss or pruning of clones targeted by vaccine-induced T cells. This provides an important reminder that even a highly effective vaccine may exert selective pressure on the tumor, potentially favouring immune-resistant populations.

Personalization will Not Necessarily Mean One Vaccine for Every Patient

Predicting neoantigens from tumor sequencing is only the first step. Fully individualized vaccines face logistical and economic challenges involving tissue acquisition, sequencing, antigen selection, manufacturing and quality control within a clinically relevant timeframe. An alternative is the use of pre-characterized antigen libraries or “warehouse” approaches, which could preserve personalization while reducing manufacturing time and complexity. At the other end, off-the-shelf approaches such as NOUS-209 target recurrent frameshift neoantigens associated with mismatch repair deficiency and Lynch syndrome, potentially extending cancer vaccination from treating established tumors to cancer interception.

NOUS-209 has advanced into Phase Ib/II development in Lynch syndrome carriers, with retreatment and longer-term follow-up selected for presentation at ESMO 2026. Its FDA Fast Track designation in 2026 further highlights interest in testing whether vaccination can target early neoplastic processes and precancerous lesions, rather than only established malignancies.

mRNA is enabling the field, but it does not define the field

The success of COVID-19 mRNA vaccines accelerated manufacturing capabilities and demonstrated the platform’s potential for rapid deployment. In oncology, mRNA offers a flexible approach to encoding multiple tumor-specific antigens, making it particularly attractive for individualized cancer vaccines.

However, mRNA is only one part of a diversifying cancer-vaccine landscape. Peptide, dendritic-cell and viral-vector platforms remain relevant, each offering distinct approaches to antigen presentation, immune activation and manufacturing.

The competition is therefore less about platform superiority and more about identifying clinically relevant antigens, generating durable immune responses and improving patient outcomes. ESMO 2026 offers an opportunity to assess whether these approaches are converging on common priorities: patient selection, antigen quality and effective combination strategies.

EVX-01 tests the durability of an AI-designed personalized approach

EVX-01 adds an AI-driven dimension to personalized cancer vaccination, combining individualized peptide selection with pembrolizumab in advanced melanoma. Previously reported two-year data showed objective responses in 12 of 16 patients, including four complete responses. Three-year clinical data are scheduled for presentation at ESMO 2026, including follow-up after subsequent EVX-01 monotherapy.

The key question is whether this approach can deliver durable clinical and immunological benefits. More broadly, EVX-01 highlights AI’s potential to prioritize promising neoantigens from tumor sequencing. However, computational prediction alone cannot establish biological relevance; AI’s true value will depend on whether better antigen selection translates into stronger immune responses and improved patient outcomes.

The Remaining Barrier Is Tumor Evolution

Even sophisticated cancer vaccines cannot overcome cancer’s evolutionary nature. Tumor heterogeneity, antigen loss, altered HLA presentation and immune escape can allow tumor cells to survive despite vaccine-induced immunity, limiting response durability.

This reinforces the importance of multi-antigen targeting, which may broaden immune recognition across tumor subclones. In pancreatic cancer, the pruning of vaccine-targeted T-cell populations in recurrent disease illustrates how immune pressure can shape tumor evolution. Future strategies may therefore prioritize not only potent neoantigens but also multiple clonal, evolutionarily stable targets to improve the durability of vaccine responses. 

Manufacturing Could Become a Clinical Differentiator

The scientific sophistication of personalized cancer vaccines creates a practical challenge: the product must reach the patient before disease progression changes the therapeutic opportunity. A personalized vaccine requires tumor tissue, sequencing, computational prediction, antigen selection, manufacturing and release testing. Every additional step introduces potential delays. This becomes particularly important in the adjuvant setting, where treatment must begin after surgery but before microscopic residual disease has the opportunity to progress. Consequently, manufacturing turnaround time could become a competitive differentiator almost as important as immunogenicity.

The field may ultimately develop into a spectrum:

• Fully individualized products offering maximal biological specificity but greater manufacturing complexity.

• Warehouse or semi-personalized approaches balancing customization with scalability.

• Off-the-shelf vaccines targeting recurrent neoantigens or predictable molecular alterations.

The winning model may differ by tumor type and treatment setting rather than being determined by a single universal technology.

Combination therapy is becoming the default development strategy

Cancer vaccines are unlikely to replace checkpoint inhibitors; their mechanisms are complementary. Vaccines broaden tumor-specific T-cell responses, while checkpoint inhibitors release inhibitory signals that suppress these cells. The V940/intismeran autogene Phase III INTerpath-001 trial, which combines the vaccine with pembrolizumab, exemplifies this strategy. Combinations with chemotherapy, targeted therapies or tumor-microenvironment modulators may also emerge. However, broader combinations are not inherently better, as added therapies can increase toxicity, complexity and cost. The key question is whether a combination delivers meaningful incremental benefit over the established treatment backbone, particularly as development advances toward registration.

From experimental promise to precision oncology

The biggest shift in cancer vaccines is not the arrival of mRNA or AI, but a more precise therapeutic approach: identifying tumor antigens that are biologically relevant, widely expressed and capable of generating durable immunity as cancer evolves.

Intismeran autogene is testing whether this strategy can deliver randomized clinical benefit, while autogene cevumeran explores durable tumor-specific immune memory. EVX-01 combines AI-driven antigen selection with personalized vaccination, NOUS-209 extends the concept toward cancer interception, and immunopeptidomics may improve target selection. Together, these approaches shift the focus beyond T-cell activation toward clinical benefit, durability and scalability. ESMO 2026 marks an important transition from demonstrating immune activation to establishing meaningful disease control. The ultimate promise of precision cancer vaccination is not simply to personalize a drug, but to use each tumor’s biology as the blueprint for treatment.